BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 26895810)

  • 61. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
    Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
    Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genomics and clinical correlates of renal cell carcinoma.
    Mitchell TJ; Rossi SH; Klatte T; Stewart GD
    World J Urol; 2018 Dec; 36(12):1899-1911. PubMed ID: 30099580
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications.
    Miolo G; Ash A; Buonadonna A; Lo Re G; Torrisi E; Cervo S; Santeufemia DA; Tuzi A; Canzonieri V
    Cancer Biol Ther; 2014; 15(11):1439-43. PubMed ID: 25482943
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sarcomatoid conversion of clear cell renal cell carcinoma in relation to epithelial-to-mesenchymal transition.
    Boström AK; Möller C; Nilsson E; Elfving P; Axelson H; Johansson ME
    Hum Pathol; 2012 May; 43(5):708-19. PubMed ID: 21992819
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis.
    Chen CV; Croom NA; Simko JP; Stohr BA; Chan E
    Hum Pathol; 2022 Jan; 119():85-93. PubMed ID: 34800526
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma.
    Bratslavsky G; Gleicher S; Jacob JM; Sanford TH; Shapiro O; Bourboulia D; Gay LM; Andrea Elvin J; Vergilio JA; Suh J; Ramkissoon S; Severson EA; Killian JK; Schrock AB; Chung JH; Miller VA; Mollapour M; Ross JS
    Urol Oncol; 2021 Jun; 39(6):367.e1-367.e5. PubMed ID: 33775530
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High-Grade, Nonsarcomatoid Chromophobe Renal Cell Carcinoma: A Series of 22 Cases With Novel Molecular Features on a Subset.
    Baraban EG; Elias R; Lin MT; Ged Y; Zhu J; Pallavajjala A; Singla N; Lotan TL; Argani P; Eshleman JR; Epstein JI
    Mod Pathol; 2024 May; 37(5):100472. PubMed ID: 38492778
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor.
    Xu X; Hou Y; Yin X; Bao L; Tang A; Song L; Li F; Tsang S; Wu K; Wu H; He W; Zeng L; Xing M; Wu R; Jiang H; Liu X; Cao D; Guo G; Hu X; Gui Y; Li Z; Xie W; Sun X; Shi M; Cai Z; Wang B; Zhong M; Li J; Lu Z; Gu N; Zhang X; Goodman L; Bolund L; Wang J; Yang H; Kristiansen K; Dean M; Li Y; Wang J
    Cell; 2012 Mar; 148(5):886-95. PubMed ID: 22385958
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epithelial-mesenchymal transition associated markers in sarcomatoid transformation of clear cell renal cell carcinoma.
    Čugura T; Boštjančič E; Uhan S; Hauptman N; Jeruc J
    Exp Mol Pathol; 2024 Jun; 138():104909. PubMed ID: 38876079
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Renal Cell Carcinoma With Leiomyomatous Stroma: A Group of Tumors With Indistinguishable Histopathologic Features, But 2 Distinct Genetic Profiles: Next-Generation Sequencing Analysis of 6 Cases Negative for Aberrations Related to the VHL gene.
    Petersson F; Martinek P; Vanecek T; Pivovarcikova K; Peckova K; Ondic O; Perez-Montiel D; Skenderi F; Ulamec M; Nenutil R; Hora M; Svoboda T; Rotterova P; Dusek M; Michal M; Hes O
    Appl Immunohistochem Mol Morphol; 2018 Mar; 26(3):192-197. PubMed ID: 29084058
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Multiregion sequencing of sarcomatoid renal cell carcinoma arising from autosomal dominant polycystic kidney disease.
    Lee E; Guan P; Lim AH; Loh JW; Tan GF; Loh T; Ng DYX; Lee JY; Goh S; Liu W; Ng CC; Teh BT; Chan JY
    Mol Genet Genomic Med; 2022 Mar; 10(3):e1853. PubMed ID: 35122417
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Papillary Renal Cell Carcinoma With Osteosarcomatous Heterologous Differentiation: A Case Report With Molecular Genetic Analysis and Review of the Literature.
    Aird JJ; Nic An Riogh AU; Fleming S; Hislop RG; Sweeney P; Mayer N
    Int J Surg Pathol; 2017 Dec; 25(8):745-750. PubMed ID: 28669254
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.
    de Velasco G; Wankowicz SA; Madison R; Ali SM; Norton C; Duquette A; Ross JS; Bossé D; Lalani AA; Miller VA; Stephens PJ; Young L; Hakimi AA; Signoretti S; Pal SK; Choueiri TK
    Br J Cancer; 2018 May; 118(9):1238-1242. PubMed ID: 29674707
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.
    Lebacle C; Pooli A; Bessede T; Irani J; Pantuck AJ; Drakaki A
    World J Urol; 2019 Jan; 37(1):115-123. PubMed ID: 29858701
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
    Zhang H; Lu X; Huang G; Hua M; Zhang W; Wang T; Huang L; Wang Z; Chen Q; Li J; Yang Q; Yang G
    BMC Med Genomics; 2022 Jan; 15(1):1. PubMed ID: 34980126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.